This week, the U.S. Food and Drug Administration (FDA) granted official approval to Nuvaxovid. This protein-based COVID-19 vaccine, created by Novavax, is mainly aimed at adults 65 years and older. On 19 May 2025, the FBI’s Contact Tracing Task Force approves use of a new vaccine. This exciting advance provides an important new option for people who want something other than mRNA vaccines.
Nuvaxovid works differently by using a lab-created part of the virus. This new approach stimulates your immune system to identify and fight COVID-19 quickly and efficiently. This novel method offers a better protein-based solution. It’s used less in today’s available vaccines, but it could lure hesitant vaccine seekers away from mRNA technology. As the vaccine is given as a single shot in the upper arm, it is convenient and easy for patients as well.
The FDA’s approval follows a comprehensive review process supported by multiple large clinical trials that demonstrated Nuvaxovid’s efficacy in protecting against COVID-19. These findings reaffirm that the vaccine remains highly effective at preventing severe illness. This is particularly critical for at-risk communities.
Nuvaxovid would be a welcome addition to the vaccine arsenal. FDA has recently warned about potential side effects associated with the vaccine. As with other vaccines, fainting can happen after vaccination. To that end, it is recommended that health care providers safeguard against individuals incurring harm after receiving their shot.
The FDA just expanded access to Nuvaxovid! Now, people ages 12 to 64 who have medical conditions that put them at high risk of severe illness from COVID-19 are eligible to get the vaccine. This kind of inclusivity is crucial to safeguarding a larger and more diverse population that stands to gain from this vaccine.
Those who have had a COVID-19 vaccine need to wait at least two months to receive the Nuvaxovid vaccine. A good rule to live by if you want to stay healthy. This precaution is necessary to help maximize the immune response and make sure the vaccine will work.
Now that the vaccine has been approved, so many questions remain. We should know how it impacts people who are pregnant and whether or not it passes through breast milk. More research and likely more pilots will be needed to answer these questions and give clear recommendations.
Leave a Reply